Nanomedicines in the Treatment of Liver Fibrosis: A Review
Xiao Du,1,2,* Runyan Niu,1,3,* Xuexue Liu,4,* Fang Wu,1,3 Xian Yang,1 Xiaolong Ma,2 Jinping Zhang,1 Haihui Zhou,5 Lihua Shao,2 Siliang Wang1 1Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 2...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-08-01
|
| Series: | International Journal of Nanomedicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/nanomedicines-in-the-treatment-of-liver-fibrosis-a-review-peer-reviewed-fulltext-article-IJN |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240047225667584 |
|---|---|
| author | Du X Niu R Liu X Wu F Yang X Ma X Zhang J Zhou H Shao L Wang S |
| author_facet | Du X Niu R Liu X Wu F Yang X Ma X Zhang J Zhou H Shao L Wang S |
| author_sort | Du X |
| collection | DOAJ |
| description | Xiao Du,1,2,* Runyan Niu,1,3,* Xuexue Liu,4,* Fang Wu,1,3 Xian Yang,1 Xiaolong Ma,2 Jinping Zhang,1 Haihui Zhou,5 Lihua Shao,2 Siliang Wang1 1Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, People’s Republic of China; 2Department of Colorectal Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, People’s Republic of China; 3Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210008, People’s Republic of China; 4Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210008, People’s Republic of China; 5Department of Pharmacy, Geriatric Hospital of Nanjing Medical University, Nanjing, 2100024, People’s Republic of China*These authors contributed equally to this workCorrespondence: Haihui Zhou; Siliang Wang, Email zhhhnj@126.com; wsl_dth@126.comAbstract: Liver fibrosis is a reversible pathological process caused by chronic liver injury, which can lead to severe complications such as liver failure and cirrhosis. Current clinical treatments mainly focus on managing the underlying causes and complications, such as using antiviral regimens for HBV/HCV infections, combining alcohol abstinence with nutritional support for alcoholic fibrosis, and emphasizing weight reduction and exercise in metabolic associated steatolipodystrophy or non-alcoholic steatohepatitis. However, traditional therapies often have limited efficacy and significant side effects. With the deepening understanding of the pathophysiology of liver fibrosis, new therapeutic targets and investigational drugs are being continuously discovered. For example, lanifibranor and efruxifermin have shown promise in clinical trials. Although methods such as FXR and PPAR agonists, fibroblast growth factor 21 analogs, and mesenchymal stem cell therapies hold potential, they are limited by suboptimal delivery to the target site and systemic adverse reactions. Nanomedicine offers a solution by enabling the direct, precise, and efficient delivery of antifibrotic agents to fibrotic sites. This review explores the pathological mechanisms of liver fibrosis, the current state of clinical treatments, and the application of nanomedicine in the diagnosis and treatment of liver fibrosis. It also discusses the challenges in translating nanomedicines from laboratory research to clinical application and suggests potential improvements, aiming to enhance the understanding of liver fibrosis and provide new insights and approaches for its reversal and potential cure.Keywords: nanomedicine, liver fibrosis, targeted therapy, drug delivery systems, combination therapy |
| format | Article |
| id | doaj-art-05965dac020b4ec6bf5dbbd595ab322b |
| institution | Kabale University |
| issn | 1178-2013 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Nanomedicine |
| spelling | doaj-art-05965dac020b4ec6bf5dbbd595ab322b2025-08-20T04:00:44ZengDove Medical PressInternational Journal of Nanomedicine1178-20132025-08-01Volume 20Issue 196419665105459Nanomedicines in the Treatment of Liver Fibrosis: A ReviewDu X0Niu R1Liu X2Wu F3Yang X4Ma X5Zhang J6Zhou H7Shao L8Wang S9Department of PharmacyDepartment of PharmacyDepartment of HematologyDepartment of HematologyDepartment of PharmacyColorectal SurgeryDepartment of PharmacyDepartment of PharmacyDepartment of Colorectal SurgeryDepartment of PharmacyXiao Du,1,2,* Runyan Niu,1,3,* Xuexue Liu,4,* Fang Wu,1,3 Xian Yang,1 Xiaolong Ma,2 Jinping Zhang,1 Haihui Zhou,5 Lihua Shao,2 Siliang Wang1 1Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, People’s Republic of China; 2Department of Colorectal Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, People’s Republic of China; 3Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210008, People’s Republic of China; 4Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210008, People’s Republic of China; 5Department of Pharmacy, Geriatric Hospital of Nanjing Medical University, Nanjing, 2100024, People’s Republic of China*These authors contributed equally to this workCorrespondence: Haihui Zhou; Siliang Wang, Email zhhhnj@126.com; wsl_dth@126.comAbstract: Liver fibrosis is a reversible pathological process caused by chronic liver injury, which can lead to severe complications such as liver failure and cirrhosis. Current clinical treatments mainly focus on managing the underlying causes and complications, such as using antiviral regimens for HBV/HCV infections, combining alcohol abstinence with nutritional support for alcoholic fibrosis, and emphasizing weight reduction and exercise in metabolic associated steatolipodystrophy or non-alcoholic steatohepatitis. However, traditional therapies often have limited efficacy and significant side effects. With the deepening understanding of the pathophysiology of liver fibrosis, new therapeutic targets and investigational drugs are being continuously discovered. For example, lanifibranor and efruxifermin have shown promise in clinical trials. Although methods such as FXR and PPAR agonists, fibroblast growth factor 21 analogs, and mesenchymal stem cell therapies hold potential, they are limited by suboptimal delivery to the target site and systemic adverse reactions. Nanomedicine offers a solution by enabling the direct, precise, and efficient delivery of antifibrotic agents to fibrotic sites. This review explores the pathological mechanisms of liver fibrosis, the current state of clinical treatments, and the application of nanomedicine in the diagnosis and treatment of liver fibrosis. It also discusses the challenges in translating nanomedicines from laboratory research to clinical application and suggests potential improvements, aiming to enhance the understanding of liver fibrosis and provide new insights and approaches for its reversal and potential cure.Keywords: nanomedicine, liver fibrosis, targeted therapy, drug delivery systems, combination therapyhttps://www.dovepress.com/nanomedicines-in-the-treatment-of-liver-fibrosis-a-review-peer-reviewed-fulltext-article-IJNNanomedicineLiver FibrosisTargeted TherapyDrug Delivery SystemsCombination therapy |
| spellingShingle | Du X Niu R Liu X Wu F Yang X Ma X Zhang J Zhou H Shao L Wang S Nanomedicines in the Treatment of Liver Fibrosis: A Review International Journal of Nanomedicine Nanomedicine Liver Fibrosis Targeted Therapy Drug Delivery Systems Combination therapy |
| title | Nanomedicines in the Treatment of Liver Fibrosis: A Review |
| title_full | Nanomedicines in the Treatment of Liver Fibrosis: A Review |
| title_fullStr | Nanomedicines in the Treatment of Liver Fibrosis: A Review |
| title_full_unstemmed | Nanomedicines in the Treatment of Liver Fibrosis: A Review |
| title_short | Nanomedicines in the Treatment of Liver Fibrosis: A Review |
| title_sort | nanomedicines in the treatment of liver fibrosis a review |
| topic | Nanomedicine Liver Fibrosis Targeted Therapy Drug Delivery Systems Combination therapy |
| url | https://www.dovepress.com/nanomedicines-in-the-treatment-of-liver-fibrosis-a-review-peer-reviewed-fulltext-article-IJN |
| work_keys_str_mv | AT dux nanomedicinesinthetreatmentofliverfibrosisareview AT niur nanomedicinesinthetreatmentofliverfibrosisareview AT liux nanomedicinesinthetreatmentofliverfibrosisareview AT wuf nanomedicinesinthetreatmentofliverfibrosisareview AT yangx nanomedicinesinthetreatmentofliverfibrosisareview AT max nanomedicinesinthetreatmentofliverfibrosisareview AT zhangj nanomedicinesinthetreatmentofliverfibrosisareview AT zhouh nanomedicinesinthetreatmentofliverfibrosisareview AT shaol nanomedicinesinthetreatmentofliverfibrosisareview AT wangs nanomedicinesinthetreatmentofliverfibrosisareview |